MCID: LPS002
MIFTS: 57

Liposarcoma

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Liposarcoma

Summaries for Liposarcoma

NIH Rare Diseases : 50 liposarcoma is a tumor that arises from fat tissue. this tumor often occurs in the thigh, legs, behind the knee, or in the abdomen, but it can be found in other parts of the body, in the retroperitoneum; and, less often, in the head and neck area. their primary occurrence in the skin is rare. because a liposarcoma may grow into surrounding tissues or organs, it is considered a malignant tumor. the world health organization classification of soft tissue tumors recognizes 5 types of liposarcomas: well differentiated, which includes the adipocytic, sclerosing, and inflammatory subtypes; dedifferentiated; myxoid; round cell; and pleomorphic. most patients with liposarcoma have no symptoms until the tumor is large and invades the neighboring organs or tissues, causing tenderness, pain, or functional problems. although surgical removal of the tumor is the curative treatment, some patients may benefit from chemotherapy and radiation. most patients with liposarcoma have no symptoms until the tumor is large and impinges on neighboring structures, causing tenderness, pain, or functional disturbances. in the retroperitoneal area, where liposarcoma is detected at a late stage, the tumor may grow to a substantial size, weighing several pounds at the time of diagnosis. in general, liposarcoma grows silently, and the patient's estimation of the clinical duration is often unreliable. the patient eventually becomes aware of a swelling or a mass and reports this finding to the physician. patients may report the following: associated episode of trauma to the region containing the mass painful swelling (occurs in one third of cases for as long as 6 mo) decreased function (ie, range of motion) numbness enlargement of varicose veins fatigue abdominal pain weight loss nausea vomiting  last updated: 6/23/2016

MalaCards based summary : Liposarcoma is related to spindle cell liposarcoma and vulvar liposarcoma, and has symptoms including fatigue, abdominal pain and weight loss. An important gene associated with Liposarcoma is FUS (FUS RNA Binding Protein), and among its related pathways/superpathways are Pathways in cancer and Endometrial cancer. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include adipocyte, bone and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Disease Ontology : 12 A lipomatous cancer that arises in fat cells in deep soft tissue retroperitoneum.

Wikipedia : 72 Liposarcoma is a cancer that arises in fat cells in deep soft tissue, such as that inside the thigh or... more...

Related Diseases for Liposarcoma

Diseases in the Liposarcoma family:

Adult Liposarcoma Inflammatory Liposarcoma

Diseases related to Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 313)
id Related Disease Score Top Affiliating Genes
1 spindle cell liposarcoma 33.2 CDKN2A DES MDM2 VIM
2 vulvar liposarcoma 32.2 CD34 FUS MB MDM2 TP53
3 cutaneous liposarcoma 32.0 CALB2 CD34 CDK4 DDIT3 MDM2
4 adult liposarcoma 30.9 CD34 CDK4 CDKN2A DDIT3 FUS HMGA2
5 aortic aneurysm 30.1 DES VIM
6 histiocytoma 30.0 DES MB TP53 VIM
7 gigantism 30.0 DES MB
8 myeloid leukemia 29.7 CDKN2A PPARG
9 myxoid liposarcoma 12.4
10 larynx liposarcoma 12.0
11 kidney liposarcoma 12.0
12 mediastinum liposarcoma 12.0
13 pleomorphic liposarcoma 11.9
14 retroperitoneal liposarcoma 11.9
15 dedifferentiated liposarcoma 11.9
16 mixed liposarcoma 11.9
17 gastric liposarcoma 11.9
18 liposarcoma of the ovary 11.9
19 myxoid liposarcoma of the ovary 11.9
20 inflammatory liposarcoma 11.8
21 liposarcoma of bone 11.8
22 sclerosing liposarcoma 11.8
23 breast liposarcoma 11.8
24 atypical lipomatous tumor 11.7
25 cellular myxoid liposarcoma 11.7
26 esophagus liposarcoma 11.7
27 pediatric liposarcoma 11.6
28 fibroblastic liposarcoma 11.6
29 intracranial liposarcoma 11.6
30 acute cholinergic dysautonomia 10.8 MDM2 TP53
31 cervical adenoid cystic carcinoma 10.8 CDKN2A TP53
32 primary pulmonary lymphoma 10.8 CDK4 MDM2
33 malignant hyperthermia susceptibility type 3 10.8 DES HMGA2
34 reactive arthritis 10.8 CDK4 MDM2
35 split hand split foot nystagmus 10.7 CDKN2A TP53
36 rnase t2-deficient leukoencephalopathy 10.7 CDK4 MDM2 TP53
37 transverse colon cancer 10.7 EWSR1 FUS HMGA2
38 epidural neoplasm 10.7 CDK4 CDKN2A MDM2
39 leiomyoma cutis 10.7 CDKN2A TP53
40 ovary rhabdomyosarcoma 10.7 DES HMGA2
41 breast epithelioid hemangioma 10.7 CDK4 MDM2 TP53
42 ascaridiasis 10.7 CDK4 MDM2 TP53
43 sparse hair-short stature-skin anomalies syndrome 10.7 DES FUS
44 rectum squamous cell carcinoma 10.7 CDKN2A MDM2 TP53
45 thyroid cancer, nonmedullary, 4 10.7 DDIT3 EWSR1 FUS
46 infantile scoliosis 10.7 DES VIM
47 penis paget's disease 10.7 CDKN2A HMGA2 TP53
48 bone ameloblastoma 10.7 CDKN2A RB1
49 bladder squamous cell carcinoma 10.7 CDKN2A MDM2 TP53
50 localized osteosarcoma 10.7 CDK4 DES MDM2

Graphical network of the top 20 diseases related to Liposarcoma:



Diseases related to Liposarcoma

Symptoms & Phenotypes for Liposarcoma

Human phenotypes related to Liposarcoma:

32 (show all 9)
id Description HPO Frequency HPO Source Accession
1 fatigue 32 occasional (7.5%) HP:0012378
2 abdominal pain 32 occasional (7.5%) HP:0002027
3 weight loss 32 occasional (7.5%) HP:0001824
4 varicose veins 32 occasional (7.5%) HP:0002619
5 sarcoma 32 hallmark (90%) HP:0100242
6 paresthesia 32 occasional (7.5%) HP:0003401
7 nausea and vomiting 32 occasional (7.5%) HP:0002017
8 subcutaneous nodule 32 hallmark (90%) HP:0001482
9 abnormality of the kidney 32 occasional (7.5%) HP:0000077

GenomeRNAi Phenotypes related to Liposarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.78 VIM
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.78 FUS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.78 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.78 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.78 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.78 VIM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.78 FUS
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.78 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.78 VIM
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.78 VIM
11 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.78 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.78 TP53
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.78 VIM FUS PPARG TP53
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 FUS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.78 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.78 FUS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.78 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.78 TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.78 PPARG
20 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.78 FUS TP53
21 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.78 FUS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.78 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.78 FUS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.78 FUS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 VIM

MGI Mouse Phenotypes related to Liposarcoma:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.36 CD34 CDK4 CDKN2A DDIT3 DES LRP1
2 behavior/neurological MP:0005386 10.31 VIM CALB2 CDK4 CDKN2A DDIT3 DES
3 cardiovascular system MP:0005385 10.3 CDK4 CDKN2A DDIT3 DES LRP1 MB
4 homeostasis/metabolism MP:0005376 10.3 CD34 CDK4 CDKN2A DDIT3 DES LRP1
5 hematopoietic system MP:0005397 10.29 CD34 CDK4 CDKN2A DDIT3 LRP1 MB
6 embryo MP:0005380 10.19 CDK4 CDKN2A LRP1 MB MDM2 PPARG
7 immune system MP:0005387 10.17 CDKN2A DDIT3 LRP1 MDM2 PPARG RB1
8 liver/biliary system MP:0005370 10.02 CDKN2A DDIT3 LRP1 MDM2 PPARG RB1
9 muscle MP:0005369 10.02 TP53 VIM CDK4 CDKN2A DES LRP1
10 integument MP:0010771 10.01 CD34 CDK4 CDKN2A MDM2 PPARG RB1
11 nervous system MP:0003631 9.9 CALB2 CDK4 CDKN2A DDIT3 LRP1 MDM2
12 neoplasm MP:0002006 9.86 PPARG RB1 TP53 CD34 CDK4 CDKN2A
13 pigmentation MP:0001186 9.35 CDK4 CDKN2A MDM2 RB1 TP53
14 reproductive system MP:0005389 9.28 TSN VIM CDK4 CDKN2A LRP1 MDM2

Drugs & Therapeutics for Liposarcoma

Drugs for Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Lenograstim Approved Phase 3,Phase 2 135968-09-1
8
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
10
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
11
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
12
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
16
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
17
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
18 Alkylating Agents Phase 3,Phase 2,Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Isophosphamide mustard Phase 3,Phase 2,Phase 1
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
23 Liver Extracts Phase 3
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
25 Etoposide phosphate Phase 3,Phase 2
26 Anti-Infective Agents Phase 3,Phase 2,Phase 1
27 Antimitotic Agents Phase 3,Phase 2
28 Antirheumatic Agents Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
31 Antimetabolites Phase 3,Phase 2,Phase 1
32 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
33 Antiviral Agents Phase 3,Phase 2,Phase 1
34 Gastrointestinal Agents Phase 3,Phase 2
35 Pharmaceutical Solutions Phase 3
36 Anti-Allergic Agents Phase 3
37 Antipruritics Phase 3
38 Dermatologic Agents Phase 3
39 Histamine Antagonists Phase 3
40 Histamine H1 Antagonists Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Neurotransmitter Agents Phase 3
43
Serotonin Phase 3 50-67-9 5202
44 Serotonin Agents Phase 3
45 Serotonin Antagonists Phase 3
46
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
47
Palbociclib Approved Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
48
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
49
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
50
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102

Interventional clinical trials:

(show top 50) (show all 112)

id Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
3 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
4 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
10 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
11 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
12 Selinexor in Advanced Liposarcoma Recruiting NCT02606461 Phase 2, Phase 3 Selinexor;Placebo
13 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
14 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
15 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
16 A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Active, not recruiting NCT01692678 Phase 3 Trabectedin;Dacarbazine
17 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
18 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
19 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
20 Brostallicin Clinical Trial for Myxoid Liposarcoma Unknown status NCT00633165 Phase 2 Brostallicin
21 Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
22 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
23 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
24 PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Completed NCT01209598 Phase 2 Palbociclib
25 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed NCT01506596 Phase 2 pazopanib
26 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
27 Rosiglitazone in Treating Patients With Liposarcoma Completed NCT00004180 Phase 2 rosiglitazone maleate
28 Troglitazone in Treating Patients With Liposarcoma Completed NCT00003058 Phase 2 troglitazone
29 A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone
30 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
31 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
32 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
33 Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Completed NCT00093080 Phase 2 ridaforolimus
34 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
35 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
36 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
37 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
38 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
39 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
40 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
41 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
42 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
43 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
44 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
45 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
46 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
47 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
48 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
49 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
50 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate

Search NIH Clinical Center for Liposarcoma

Cochrane evidence based reviews: liposarcoma

Genetic Tests for Liposarcoma

Anatomical Context for Liposarcoma

MalaCards organs/tissues related to Liposarcoma:

39
Adipocyte, Bone, Skin, Breast, T Cells, Liver, Colon

Publications for Liposarcoma

Articles related to Liposarcoma:

(show top 50) (show all 1319)
id Title Authors Year
1
Incidentally discovered well-differentiated retroperitoneal liposarcoma with inguinal canal herniation: report of 2 cases. ( 28491177 )
2017
2
Surgical resection of a well-differentiated inflammatory liposarcoma of the middle mediastinum: a case report. ( 28932587 )
2017
3
A huge primary pleomorphic liposarcoma of the left atrium. ( 28747948 )
2017
4
Endoscopic submucosal dissection of a huge esophageal atypical lipomatous tumor (well-differentiated liposarcoma) with a 4-year recurrence-free survival. ( 28719927 )
2017
5
Resection of giant mediastinal liposarcoma via 'a8L shape' incision. ( 28044001 )
2017
6
FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. ( 28637688 )
2017
7
Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma. ( 28099935 )
2017
8
Giant Esophageal Liposarcoma. ( 28840446 )
2017
9
p16 Immunohistochemistry is Less Useful Than MDM2 and CDK4 to Distinguish Dedifferentiated Liposarcomas From Other Retroperitoneal Mimics. ( 26509911 )
2017
10
Eribulin: an effective therapeutic option in liposarcoma. ( 28890295 )
2017
11
Scattered genomic amplification in dedifferentiated liposarcoma. ( 28652867 )
2017
12
Retroperitoneal Liposarcoma: An Aggressive Strategy to Maximize Disease Control. ( 28463147 )
2017
13
Extensive left ventricular, pulmonary artery, and pericardial metastasis from myxoid liposarcoma 16 years after the initial detection of the primary tumour: a case report and review of the literature. ( 28866706 )
2017
14
Primary atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) of the breast. ( 28845581 )
2017
15
Propranolol 18F-FDG PET/CT: A Noninvasive Approach for Differential Diagnosis of Hibernoma and Liposarcoma. ( 28902737 )
2017
16
Preoperative Radiation Therapy With Simultaneous Integrated Boost Dose Escalation for Optimal Local Control of Retroperitoneal Dedifferentiated Liposarcoma. ( 28463146 )
2017
17
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. ( 28854066 )
2017
18
Pedunculated, well differentiated liposarcoma of the oesophagus mimicking giant fibrovascular polyp. ( 28853590 )
2017
19
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. ( 28947876 )
2017
20
Dedifferentiated Liposarcoma With Epithelioid/Epithelial Features. ( 28719466 )
2017
21
Pleomorphic liposarcoma of the head and neck: Presentation of two cases and literature review. ( 28528729 )
2017
22
The Conundrum of Retroperitoneal Liposarcoma-To Be More Aggressive or Less Aggressive? ( 28463143 )
2017
23
Dedifferentiated liposarcoma of the lower extremity with low-grade dedifferentiation and low-grade osteosarcomatous component. ( 27909788 )
2017
24
A newly emerged osteosarcomatous dedifferentiation of liposarcoma in lung metastasis - a potential diagnostic pitfall. ( 27879024 )
2017
25
Giant retroperitoneal dedifferentiated liposarcoma. ( 28098568 )
2017
26
Primary Myxoid Liposarcoma of the Upper Thoracic Spine in an Elderly Patient. ( 28936087 )
2017
27
Effective apatinib treatment of pleomorphic liposarcoma: A case report. ( 28816958 )
2017
28
Comparison of retroperitoneal liposarcoma extending into the inguinal canal and inguinoscrotal liposarcoma. ( 28930047 )
2017
29
Neuropraxia following resection of a retroperitoneal liposarcoma. ( 28601782 )
2017
30
Treatment Recommendations for Retroperitoneal Liposarcoma. ( 28463145 )
2017
31
Mediastinal dedifferentiated liposarcoma. ( 28707566 )
2017
32
Clinicopathological characteristics and experience in the treatment of giant retroperitoneal liposarcoma: A case report and review of the literature. ( 28758856 )
2017
33
Malignant solitary fibrous tumour of the kidney with lymph node and liver metastases: beware of STAT6 expression in dedifferentiated liposarcoma with a solitary fibrous tumour-like morphology. ( 28822554 )
2017
34
MDM4 amplification in a case of de-differentiated liposarcoma and in-silico data supporting an oncogenic event alternative to MDM2 amplification in a subset of cases. ( 28756620 )
2017
35
High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. ( 28654818 )
2017
36
Dedifferentiated Liposarcoma Mimicking a Primary Colon Mass. ( 28950740 )
2017
37
Primary colonic well-differentiatedA /A dedifferentiated liposarcoma of the ascending colon: a case report. ( 28856628 )
2017
38
Pazopanib for advanced liposarcoma. ( 28844815 )
2017
39
A novel long noncoding RNA PILRLS promote proliferation through TCL1A by activing MDM2 in Retroperitoneal liposarcoma. ( 28129655 )
2017
40
TP53INP2-related basal autophagy is involved in the growth and malignant progression in human liposarcoma cells. ( 28131096 )
2017
41
Dedifferentiated Liposarcoma in the Spermatic Cord Finally Diagnosed at 7th Resection of Recurrence: A Case Report and Bibliographic Consideration. ( 28878655 )
2017
42
PRG4 expression in myxoid liposarcoma maintains tumor cell growth through suppression of an antitumor cytokine IL-24. ( 28192118 )
2017
43
Association of Li-Fraumeni Syndrome With Small Cell Carcinoma of the Ovary, Hypercalcemic Type and Concurrent Pleomorphic Liposarcoma of the Cervix. ( 28177947 )
2017
44
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen. ( 28774898 )
2017
45
Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. ( 28928422 )
2017
46
Resectable primary pleural myxoid liposarcoma with a pedicle: report of a rare case and literature review. ( 28449500 )
2017
47
Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma Developed in a Patient with Progressive Muscular Dystrophy: A Case Report and Review of the Literature. ( 28634560 )
2017
48
Paraneoplastic Cerebellar Degeneration Associated with Pelvic Liposarcoma: A Rare Case Report. ( 28092914 )
2017
49
Radical Nephrectomy for Primary Retroperitoneal Liposarcoma Near the Kidney has a Beneficial Effect on Disease-Free Survival. ( 28808758 )
2017
50
Pleomorphic myxoid liposarcoma in an adolescent with Li-Fraumeni syndrome. ( 28160093 )
2017

Variations for Liposarcoma

Cosmic variations for Liposarcoma:

9 (show all 36)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11333 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 11
2 COSM44112 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.640C>T p.H214Y 11
3 COSM10647 TP53 soft tissue,fat,liposarcoma,pleomorphic c.404G>T p.C135F 11
4 COSM1651764 RB1 soft tissue,fat,liposarcoma,pleomorphic c.1818T>A p.Y606* 11
5 COSM763 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1633G>A p.E545K 11
6 COSM24452 NF1 soft tissue,fat,liposarcoma,pleomorphic c.1105C>T p.Q369* 11
7 COSM28019 NF1 soft tissue,fat,liposarcoma,pleomorphic c.4006C>T p.Q1336* 11
8 COSM517 KRAS soft tissue,fat,liposarcoma,myxoid-round cell c.34G>A p.G12S 11
9 COSM1651756 KIT soft tissue,fat,liposarcoma,myxoid-round cell c.2334G>C p.K778N 11
10 COSM11245 TP53 soft tissue,fat,liposarcoma,NS c.430C>T p.Q144* 10
11 COSM44723 TP53 soft tissue,fat,liposarcoma,NS c.674T>C p.V225A 10
12 COSM10646 TP53 soft tissue,fat,liposarcoma,NS c.725G>A p.C242Y 10
13 COSM44094 TP53 soft tissue,fat,liposarcoma,NS c.716A>G p.N239S 10
14 COSM6901 TP53 soft tissue,fat,liposarcoma,NS c.559+1G>A p.? 10
15 COSM43663 TP53 soft tissue,fat,liposarcoma,NS c.826G>C p.A276P 10
16 COSM10941 TP53 soft tissue,fat,liposarcoma,NS c.730G>A p.G244S 10
17 COSM44512 TP53 soft tissue,fat,liposarcoma,NS c.740A>G p.N247S 10
18 COSM11059 TP53 soft tissue,fat,liposarcoma,NS c.713G>A p.C238Y 10
19 COSM10654 TP53 soft tissue,fat,liposarcoma,NS c.637C>T p.R213* 10
20 COSM775 PIK3CA soft tissue,fat,liposarcoma,NS c.3140A>G p.H1047R 10
21 COSM12458 PIK3CA soft tissue,fat,liposarcoma,NS c.1634A>C p.E545A 10
22 COSM760 PIK3CA soft tissue,fat,liposarcoma,NS c.1624G>A p.E542K 10
23 COSM21467 PIK3CA soft tissue,fat,liposarcoma,NS c.1612G>A p.D538N 10
24 COSM25083 PIK3CA soft tissue,fat,liposarcoma,NS c.1627A>G p.I543V 10
25 COSM532 KRAS soft tissue,fat,liposarcoma,NS c.38G>A p.G13D 10
26 COSM1290 KIT soft tissue,fat,liposarcoma,NS c.1727T>C p.L576P 10
27 COSM487 HRAS soft tissue,fat,liposarcoma,NS c.37G>A p.G13S 10
28 COSM480 HRAS soft tissue,fat,liposarcoma,NS c.34G>A p.G12S 10
29 COSM720 FGFR3 soft tissue,fat,liposarcoma,NS c.1949A>T p.K650M 10
30 COSM601 FGFR1 soft tissue,fat,liposarcoma,NS c.374C>T p.S125L 10
31 COSM5743 CTNNB1 soft tissue,fat,liposarcoma,NS c.117C>T p.A39A 10
32 COSM5708 CTNNB1 soft tissue,fat,liposarcoma,NS c.119C>T p.T40I 10
33 COSM5676 CTNNB1 soft tissue,fat,liposarcoma,NS c.122C>T p.T41I 10
34 COSM476 BRAF soft tissue,fat,liposarcoma,NS c.1799T>A p.V600E 10
35 COSM1745010 MYOD1 soft tissue,upper leg,rhabdomyosarcoma,sclerosing c.365T>G p.L122R 4
36 COSM483 HRAS soft tissue,upper leg,malignant fibrous histiocytoma-pleomorphic sarcoma,myxoid c.35G>T p.G12V 4

Copy number variations for Liposarcoma from CNVD:

7 (show all 36)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13334 1 1 124300000 Gain Liposarcoma
2 16445 1 124300000 247249719 Loss Liposarcoma
3 20078 1 15300000 163800000 Amplification COAS1 Liposarcoma
4 20079 1 15300000 163800000 Amplification COAS2 Liposarcoma
5 20080 1 15300000 163800000 Amplification COAS3 Liposarcoma
6 20084 1 15300000 212100000 Gain Liposarcoma
7 42815 10 40300000 135374737 Loss Liposarcoma
8 55437 11 52900000 134452384 Loss Liposarcoma
9 61489 12 1 14800000 Loss Liposarcoma
10 67172 12 37282278 37312244 Amplified CHOP Liposarcoma
11 67787 12 44600000 69800000 Gain CDK4 liposarcomas
12 67788 12 44600000 69800000 Gain HMGA2 liposarcomas
13 67789 12 44600000 69800000 Gain MDM2 liposarcomas
14 69651 12 56140200 56152312 Amplified GLI1 Liposarcoma
15 69861 12 56374152 56401607 Amplified OS9 Liposarcoma
16 69873 12 56425050 56428293 Amplified TSPAN31 Liposarcoma
17 69880 12 56428269 56432431 Amplified CDK4 Liposarcoma
18 70737 12 64503703 64646338 Amplified HMGA2 Liposarcoma
19 71088 12 67488246 67520481 Amplified MDM2 Liposarcoma
20 77049 13 39500000 52200000 Loss Liposarcoma
21 77649 13 46200000 52200000 Deletion RB1 Liposarcoma
22 78496 13 52200000 114142980 Loss Liposarcoma
23 106733 17 1 11200000 Deletion Liposarcoma
24 108852 17 23200000 28800000 Deletion Liposarcoma
25 139560 2 183406981 183439743 Amplified OS1 Liposarcoma
26 149783 2 93300000 242951149 Gain Liposarcoma
27 149786 2 93300000 242951149 Loss Liposarcoma
28 166153 3 1 91700000 Gain Liposarcoma
29 166161 3 1 91700000 Loss Liposarcoma
30 179460 3 91700000 199501827 Gain Liposarcoma
31 187537 4 50700000 191273063 Loss Liposarcoma
32 191663 5 1 45800000 Gain Liposarcoma
33 200009 5 47700000 180857866 Gain Liposarcoma
34 210239 6 29900000 45200000 Gain Liposarcoma
35 217105 7 1 59100000 Gain Liposarcoma
36 225569 7 47600000 107200000 Gain Liposarcoma

Expression for Liposarcoma

Search GEO for disease gene expression data for Liposarcoma.

Pathways for Liposarcoma

Pathways related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 35)
id Super pathways Score Top Affiliating Genes
1 12.53 CDK4 CDKN2A MDM2 PPARG RB1 TP53
2
Show member pathways
12.49 CDK4 CDKN2A MDM2 PPARG RB1 TP53
3
Show member pathways
12.49 CDK4 CDKN2A MDM2 RB1 TP53
4 12.43 CDKN2A HMGA2 MDM2 TP53 VIM
5 12.36 CDK4 RB1 TP53 VIM
6 12.36 CDK4 CDKN2A RB1 TP53
7 12.35 CDK4 CDKN2A MDM2 RB1 TP53 VIM
8
Show member pathways
12.3 CDK4 CDKN2A RB1 TP53
9
Show member pathways
12.29 CDK4 CDKN2A MDM2 RB1 TP53
10 12.27 CDK4 CDKN2A MDM2 RB1 TP53
11 12.24 MDM2 RB1 TP53 VIM
12 12.21 DDIT3 EWSR1 FUS YBX1
13
Show member pathways
12.2 CDK4 MDM2 RB1 TP53
14 12.13 CDK4 CDKN2A MDM2 RB1 TP53
15 12.08 CDK4 MDM2 RB1 TP53
16 12 CDK4 CDKN2A MDM2 TP53
17 11.99 CDKN2A MDM2 RB1 TP53
18 11.93 CDK4 RB1 TP53 VIM
19 11.86 CDKN2A MDM2 RB1 TP53
20 11.82 CD34 DES PPARG
21 11.76 CDK4 RB1 TP53
22 11.76 CDK4 CDKN2A MDM2 RB1 TP53
23 11.72 CDK4 MDM2 RB1 TP53
24 11.68 CDKN2A MDM2 TP53
25
Show member pathways
11.68 CDKN2A MDM2 TP53
26 11.54 MDM2 PPARG RB1
27 11.52 CDKN2A MDM2 TP53
28 11.48 CDKN2A RB1 TP53
29 11.42 CDK4 CDKN2A MDM2 RB1 TP53
30 11.42 DDIT3 EWSR1 FUS HMGA2 MDM2 PPARG
31 11.4 CDK4 MDM2 TP53
32 11.33 CDK4 MDM2 RB1 TP53
33 11.06 CDK4 CDKN2A MDM2 TP53
34
Show member pathways
11.01 CDKN2A MDM2 TP53
35 10.6 CDKN2A MDM2 RB1 TP53

GO Terms for Liposarcoma

Cellular components related to Liposarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.85 CDK4 CDKN2A EWSR1 LRP1 MDM2 TP53
2 cytoplasm GO:0005737 9.83 CALB2 CD34 CDK4 CDKN2A DDIT3 DES
3 senescence-associated heterochromatin focus GO:0035985 8.62 CDKN2A HMGA2
4 cytosol GO:0005829 10.03 CALB2 CDK4 CDKN2A DDIT3 DES LRP1
5 nucleoplasm GO:0005654 10.02 CDK4 CDKN2A DDIT3 FUS HMGA2 MDM2
6 nucleus GO:0005634 10 CALB2 CDK4 CDKN2A DDIT3 EWSR1 FUS

Biological processes related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.95 CDK4 CDKN2A DDIT3 HMGA2 RB1 TP53
2 positive regulation of transcription, DNA-templated GO:0045893 9.91 CDKN2A DDIT3 HMGA2 PPARG RB1 TP53
3 positive regulation of apoptotic process GO:0043065 9.85 CDK4 CDKN2A HMGA2 PPARG TP53
4 cell cycle arrest GO:0007050 9.71 CDKN2A DDIT3 RB1 TP53
5 Ras protein signal transduction GO:0007265 9.7 CDKN2A RB1 TP53
6 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.7 DDIT3 HMGA2 MDM2 PPARG RB1 TP53
7 negative regulation of neuron projection development GO:0010977 9.69 LRP1 MDM2 VIM
8 positive regulation of transcription regulatory region DNA binding GO:2000679 9.59 HMGA2 RB1
9 replicative senescence GO:0090399 9.58 CDKN2A TP53
10 ER overload response GO:0006983 9.58 DDIT3 TP53
11 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.57 DDIT3 TP53
12 positive regulation of cellular senescence GO:2000774 9.56 CDKN2A HMGA2
13 negative regulation of telomerase activity GO:0051974 9.55 PPARG TP53
14 enucleate erythrocyte differentiation GO:0043353 9.37 MB RB1
15 positive regulation of gene expression GO:0010628 9.35 CD34 HMGA2 MDM2 TP53 VIM
16 cellular response to actinomycin D GO:0072717 9.32 MDM2 TP53
17 senescence-associated heterochromatin focus assembly GO:0035986 9.26 CDKN2A HMGA2
18 amyloid fibril formation GO:1990000 9.24 MDM2
19 negative regulation of transcription, DNA-templated GO:0045892 9.17 CDKN2A DDIT3 HMGA2 MDM2 PPARG RB1
20 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.04 CDKN2A DDIT3 HMGA2 PPARG RB1 TP53

Molecular functions related to Liposarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.97 CDKN2A DDIT3 FUS HMGA2 PPARG RB1
2 enzyme binding GO:0019899 9.65 HMGA2 MDM2 PPARG RB1 TP53
3 identical protein binding GO:0042802 9.61 DES EWSR1 FUS MDM2 PPARG RB1
4 disordered domain specific binding GO:0097718 9.33 MDM2 RB1 TP53
5 transcription factor binding GO:0008134 9.17 CD34 CDKN2A DDIT3 HMGA2 PPARG RB1

Sources for Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....